AstraZeneca has struck a $95 million deal to buy a FDA priority review voucher from Swedish Orphan Biovitrum. The purchase comes as AstraZeneca enters a 12-month period in which it plans to file for approval of about 10 assets.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,